Medicine
Nuzolvence 3 g powder for oral suspension
Nuzolvence 3 g powder for oral suspension is a prescription medicine containing Zoliflodacin for oral use, marketed by La Jolla Pharmaceutical, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. NUZOLVENCE should be stored in the original packaging at room…
Key facts
- Active ingredient (INN)
- Zoliflodacin
- Brand
- Nuzolvence
- Strength
- 3 g
- Dosage form
- Powder for oral suspension
- Route
- Oral
- Packs
- 1 packet
- Marketing authorisation holder
- La Jolla Pharmaceutical
- Manufacturer
- La Jolla Pharmaceutical
- Origin register
- US FDA, United States
- Storage
- Do not freeze. NUZOLVENCE should be stored in the original packaging at room temperature 20 °C to 25 °C (68 °F to 77 °F), excursions permitted to 15 °C to 30 °C (59 °F to 86 °F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 9 October 2026
- Identifiers
- RxCUI 2739783, 2739789DailyMed set ID 4beda35a-21b0-4b34-84ea-be6ea8cae50fNDC 68547-915Application NDA219491
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 packet in 1 carton / 1 for suspension in 1 packet | 68547-915-10 | La Jolla Pharmaceutical | 9 October 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 12 December 2025 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Zoliflodacin is a prescription medicine indicated for the treatment of uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae in adults and pediatric patients 12 years of age and older, weighing at least 35 kg, among other approved uses. MedsAcross supplies Zoliflodacin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ZoliflodacinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- NUZOLVENCE prescribing information (La Jolla Pharmaceutical) · U.S. National Library of Medicine, DailyMed
Need Nuzolvence 3 g powder for oral suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.